ES2156991T3 - Procedimiento de produccion de albumina de elevada pureza. - Google Patents

Procedimiento de produccion de albumina de elevada pureza.

Info

Publication number
ES2156991T3
ES2156991T3 ES96904190T ES96904190T ES2156991T3 ES 2156991 T3 ES2156991 T3 ES 2156991T3 ES 96904190 T ES96904190 T ES 96904190T ES 96904190 T ES96904190 T ES 96904190T ES 2156991 T3 ES2156991 T3 ES 2156991T3
Authority
ES
Spain
Prior art keywords
albumin
affinity
chromatography
positive mode
albumine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904190T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Robert Delta Bio Goodey
Darrell Delta Biotechnol Sleep
Urk Hendrik Delta Biotechn Van
Stephen Delta Biotec Berezenko
John Rodney Delta Biot Woodrow
Richard Alan Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ES2156991T3 publication Critical patent/ES2156991T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ES96904190T 1995-05-25 1996-02-29 Procedimiento de produccion de albumina de elevada pureza. Expired - Lifetime ES2156991T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/378,859 US5728553A (en) 1992-09-23 1995-05-25 High purity albumin and method of producing

Publications (1)

Publication Number Publication Date
ES2156991T3 true ES2156991T3 (es) 2001-08-01

Family

ID=23494845

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96904190T Expired - Lifetime ES2156991T3 (es) 1995-05-25 1996-02-29 Procedimiento de produccion de albumina de elevada pureza.
ES00201960T Expired - Lifetime ES2219257T3 (es) 1995-05-25 1996-02-29 Albumina de elevada pureza producida por un procedimiento que comprende varias etapas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00201960T Expired - Lifetime ES2219257T3 (es) 1995-05-25 1996-02-29 Albumina de elevada pureza producida por un procedimiento que comprende varias etapas.

Country Status (15)

Country Link
US (6) US5728553A (https=)
EP (2) EP0828759B1 (https=)
JP (4) JP4040088B2 (https=)
KR (2) KR100543612B1 (https=)
CN (4) CN100455597C (https=)
AT (2) ATE198482T1 (https=)
AU (1) AU698409B2 (https=)
CA (1) CA2220923C (https=)
DE (2) DE69632353T2 (https=)
DK (2) DK0828759T3 (https=)
ES (2) ES2156991T3 (https=)
GR (1) GR3035651T3 (https=)
MX (1) MX9709108A (https=)
PT (2) PT828759E (https=)
WO (1) WO1996037515A1 (https=)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE19538625C2 (de) * 1995-10-17 1999-08-12 Sartorius Gmbh Verfahren zur Abtrennung von Albumin aus Serum durch Membranionenaustauschchromatographie
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ATE241695T1 (de) * 1996-03-13 2003-06-15 Delta Biotechnology Ltd Gärungs-steuerungssysteme
AU2007200859A1 (en) * 1999-01-30 2007-03-22 Novozymes Delta Limited Process
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
FR2792650B1 (fr) 1999-04-20 2003-02-28 Oreal Equivalent de peau agee, son procede de preparation et son utilisation
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CN100553636C (zh) 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
JP4798832B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
ATE331735T1 (de) * 2000-10-24 2006-07-15 Chemo Sero Therapeut Res Inst Verfahren zur monomerisierung von humanen serumalbumin-polymeren
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004536081A (ja) * 2001-06-13 2004-12-02 トーラス エイチエスエイ エルエルシー ヒト血清アルブミンの精製
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
JP2003040798A (ja) * 2001-07-26 2003-02-13 Nihon Pharmaceutical Co Ltd 低アルミニウム含有アルブミン製剤およびその製造法
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20080167238A1 (en) * 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
EP1465869B1 (en) * 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US8013611B2 (en) * 2006-07-14 2011-09-06 Reserve Power Cell, Llc Vehicle battery product and battery monitoring system
US7339347B2 (en) 2003-08-11 2008-03-04 Reserve Power Cell, Llc Apparatus and method for reliably supplying electrical energy to an electrical system
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
US9057061B2 (en) * 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
KR20070020204A (ko) 2004-01-20 2007-02-20 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 2가 양이온 존재 하에서 가열 처리에 의한 인간 혈청알부민의 제조 방법
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006094185A2 (en) * 2005-03-03 2006-09-08 Dmi Biosciences Inc. Quantification of proteins
US7598700B2 (en) * 2005-03-30 2009-10-06 Reserve Power Cell, Llc Tamper resistant battery and battery warranty and performance tracking system
MY144344A (en) * 2005-04-08 2011-09-15 Ciba Holding Inc Adsorbents comprising anthraquinone dye-ligands for the separation of biological materials
DE102005023155A1 (de) * 2005-05-13 2006-11-16 Albutec Gmbh Albuminlösung
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
GB0518460D0 (en) * 2005-09-09 2005-10-19 Univ Nottingham Trent Protein assay
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
JP2007284425A (ja) * 2006-03-20 2007-11-01 Nokodai Tlo Kk タンパク質の精製方法
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
EP2049560B1 (en) * 2006-07-13 2013-05-15 Novozymes Biopharma DK A/S Process for preparing particles of proteinaceous material
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US10829733B2 (en) * 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
CN101104635B (zh) * 2007-04-30 2010-11-03 北京济普霖生物技术有限公司 一种从转基因牛乳中纯化重组人α-乳清白蛋白的方法
WO2009019314A1 (en) 2007-08-08 2009-02-12 Novozymes A/S Transferrin variants and conjugates
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
EP2261661A4 (en) * 2008-03-31 2011-04-20 Sekisui Medical Co Ltd CLEANED SERUM ALBUMIN AND IMMUNOLOGY MEASUREMENT PROCESS
RU2010151453A (ru) * 2008-05-15 2012-06-20 Р-Тек Уено, Лтд. (Jp) Фармацевтическая композиция для лечения сухости глаз и/или повреждения конъюнктивы и роговицы
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
DK3381933T3 (da) 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
JP2012518409A (ja) * 2009-02-20 2012-08-16 ベントリア・バイオサイエンス タンパク質の組み合わせを含有する細胞培養培地
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
DK2427486T3 (en) * 2009-05-07 2015-05-26 Novozymes Biopharma Dk As A process for purifying albumin
CN102612362A (zh) 2009-08-05 2012-07-25 皮里斯股份公司 脂质运载蛋白突变蛋白的控制释放制剂
DK2467399T3 (en) * 2009-08-20 2017-01-23 Baxalta Inc Purification of vWF for increased removal of non-lipid-enveloped viruses
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
RU2707126C2 (ru) 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
CA2787942A1 (en) * 2010-01-25 2011-07-28 Ventria Bioscience Methods & compositions for improving protein production
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
PL221899B1 (pl) 2011-05-06 2016-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Czysta albumina oraz sposób jej otrzymywania i detekcji
JP6247210B2 (ja) 2011-07-05 2017-12-13 アルブミディクス アクティーゼルスカブ アルブミン製剤及び用途
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA028343B1 (ru) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Лечение дегенеративного заболевания сустава
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3842058B1 (en) 2011-12-13 2023-08-23 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US20140031527A1 (en) * 2012-07-27 2014-01-30 Csl Limited Method for polishing albumin
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
JP6128677B2 (ja) * 2013-02-05 2017-05-17 公立大学法人大阪市立大学 神経細胞の遊走障害を伴う疾患の判定方法及びその利用
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
CN103694343B (zh) * 2013-12-26 2016-05-25 扬州艾迪生物科技有限公司 一种从尿液中制备人血白蛋白的方法
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US20170044210A1 (en) * 2014-04-30 2017-02-16 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
CN104628830A (zh) * 2015-01-23 2015-05-20 深圳康泰生物制品股份有限公司 重组酿酒酵母表达HBsAg的制备工艺及其分离纯化工艺、HBsAg和乙肝疫苗
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
CR20170425A (es) 2015-02-18 2017-11-22 Sanofi Sa Nuevas proteínas específicas para pioverdina y pioquelina
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN114573680A (zh) 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
MX2017014730A (es) 2015-05-18 2018-06-28 Pieris Pharmaceuticals Gmbh Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
EP3298030B1 (en) 2015-05-18 2023-01-18 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
WO2017009456A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
FR3040882A1 (fr) * 2015-09-10 2017-03-17 Lab Francais Du Fractionnement Composition liquide d'albumine humaine a usage therapeutique
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
EP3394243A1 (en) 2015-12-22 2018-10-31 Albumedix Ltd. Improved protein expression strains
KR102050852B1 (ko) * 2016-03-11 2019-12-03 주식회사 스템온 세포 리프로그래밍 장치
WO2018033482A1 (en) * 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
KR102662031B1 (ko) 2016-10-04 2024-05-03 알부메딕스 리미티드 재조합 효모-유래 혈청 알부민의 용도
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CA3050194A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
AU2018233184B2 (en) * 2017-03-16 2022-06-16 Evolve Biologics Inc. Method for purification of albumin
US11130979B2 (en) 2017-06-20 2021-09-28 Albumedix Ltd Protein expression strains
CN110563833A (zh) * 2018-06-06 2019-12-13 中国计量科学研究院 一种人血白蛋白标准物质原料的制备方法及其产品和应用
FI3830120T3 (fi) 2018-07-31 2023-06-13 Pieris Pharmaceuticals Gmbh CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
CN109734796B (zh) * 2019-02-01 2022-04-15 广州蕊特生物科技有限公司 一种从溶血血清中分离白蛋白的工艺
CN109776673B (zh) * 2019-02-20 2022-03-29 天津理工大学 一种适合中试量产的高纯度牛血清白蛋白纯化工艺
SG11202106353VA (en) 2019-02-26 2021-07-29 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
CN110229229A (zh) * 2019-07-10 2019-09-13 甘肃养泰和生物科技有限公司 一种从牛血浆中提取纯化细胞培养级牛血清白蛋白的生产方法及其应用
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
EP4161957A1 (en) 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Multimeric immunomodulator targeting 4-1bb
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
CA3200309A1 (en) * 2020-10-30 2022-05-05 Shenzhen Protgen Ltd. Use of human serum albumin in treatment of diseases
KR20230060524A (ko) 2020-12-08 2023-05-04 통화 안레이트 바이오파마슈티컬 컴퍼니 리미티드 재조합 단백질의 정제 방법
CN112592399B (zh) * 2020-12-15 2024-04-12 甘肃养泰和生物科技有限公司 一种从牛血清中分离牛血清白蛋白的制备方法及装置
JP2024500994A (ja) 2020-12-28 2024-01-10 デボル，インコーポレイテッド タンパク質及び多官能化変性ポリエチレングリコール系架橋剤を含む反応性乾燥粉末状止血用材料
US20240228562A1 (en) 2021-04-08 2024-07-11 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
CN113735963A (zh) * 2021-09-10 2021-12-03 山东健通生物科技有限公司 一种重组人血清白蛋白纯化过程去除色素的方法
CN114316088B (zh) * 2021-12-22 2022-09-09 中国水产科学研究院黄海水产研究所 亲和树脂、制备方法及其在分离纯化藻蓝蛋白中的应用
JP2025532652A (ja) 2022-09-21 2025-10-01 シージェン インコーポレイテッド Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法
CN115763878A (zh) * 2022-11-24 2023-03-07 大连融科储能技术发展有限公司 一种抑制锌铁液流电池水跨膜迁移或渗透的方法
CN116120392B (zh) * 2023-04-18 2023-08-01 上海健士拜生物科技有限公司 聚体蛋白的纯化方法
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228
WO2026074121A1 (en) 2024-10-02 2026-04-09 Sartorius Albumedix Limited Albumin formulations and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019919D0 (en) * 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
US2433905A (en) 1943-11-01 1948-01-06 Jr Walter L Hughes Method for the crystallization of albumin and the preparation of protein products therefrom
AT317418B (de) * 1972-06-16 1974-08-25 Brigitte Panhofer Verfahren zur Herstellung von intravenös beim Menschen anwendbarem Humanalbumin aus menschlichen Placenten
FR2190437B1 (https=) 1972-07-05 1975-08-08 Merieux Inst
CA1044537A (en) 1973-05-09 1978-12-19 Amf Incorporated Filter medium and process
DE2537123A1 (de) * 1975-08-20 1977-03-03 New Zealand Inventions Dev Verfahren zur herstellung von albumin
SE405549B (sv) * 1975-10-09 1978-12-18 Pharmacia Fine Chemicals Ab Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US4075197A (en) * 1976-09-20 1978-02-21 Monsanto Company Serum albumin production
IN150740B (https=) 1978-11-24 1982-12-04 Hoffmann La Roche
US4228154A (en) * 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4222934A (en) * 1979-04-12 1980-09-16 American National Red Cross Preparation of albumin using ethanol
GB2053926B (en) 1979-07-20 1983-02-23 Atkinson A Albumin extraction by affinity chromatography
US4350156A (en) * 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
IL66614A (en) * 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
US4391801A (en) 1981-10-29 1983-07-05 Cutter Laboratories, Inc. Plasma protein fraction substantially free of acetate ions
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4748120A (en) * 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
DE3344656A1 (de) * 1983-12-09 1985-06-13 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer serumproteinloesung
CA1286622C (en) * 1986-04-28 1991-07-23 Chokyun Rha Method for clarifying and stabilizing cell culture media
JPS62294621A (ja) 1986-06-13 1987-12-22 Green Cross Corp:The アルブミンの回収方法
JPS6383100A (ja) * 1986-09-26 1988-04-13 Green Cross Corp:The ヒト尿中アルブミンの製造方法
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
IL88326A (en) 1987-11-18 1993-03-15 Gist Brocades Nv Purification of serum albumin
US4990447A (en) * 1988-06-24 1991-02-05 Gist-Brocades Nv Process for the purification of serum albumin
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
FR2648048B1 (fr) * 1989-06-08 1994-06-03 Lille Transfusion Sanguine Procede de preparation de solutions d'albumine purifiee
GB8913586D0 (en) 1989-06-13 1989-08-02 Technicol Limited A method of determining the glycosylated protein level of a sample and an apparatus for use in the method
JPH0768137B2 (ja) * 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
SE500110C2 (sv) 1989-06-27 1994-04-18 Kabi Pharmacia Ab Sätt att rena ett protein från därtill bundna flervärda metalljoner
JPH0671434B2 (ja) 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
US5250662A (en) * 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
CA2022165C (en) 1989-10-05 1999-11-23 Chong E. Chang Albumin purification
EP0452753B1 (en) * 1990-04-19 2004-06-23 Bayer Corporation Method for preparing essentially monomeric normal serum albumin (human)
JP3230091B2 (ja) * 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
JP2982296B2 (ja) 1990-11-19 1999-11-22 吉富製薬株式会社 アルブミン含有水溶液の精製法
JP2949846B2 (ja) 1990-11-30 1999-09-20 吉富製薬株式会社 アルブミン製剤の保存方法
FR2672604B1 (fr) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5284777A (en) 1991-03-04 1994-02-08 Isolab, Inc. Combined glycated hemoglobin and immunoturbidometric glycated albumin assay from whole blood lysate
US5330901A (en) * 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
EP0933083A1 (en) * 1991-07-12 1999-08-04 Dsm N.V. Process for the purification of serum albumin
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
US5281582A (en) * 1992-02-27 1994-01-25 Alliance Pharmaceuticals, Corp. Serum growth factor
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JP3360315B2 (ja) * 1992-07-31 2002-12-24 三菱ウェルファーマ株式会社 ヒト血清アルブミンの高度精製方法
DE4244915C2 (de) 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CN1055095C (zh) * 1992-12-11 2000-08-02 上海莱士血制品有限公司 白蛋白的纯化方法
CA2116385A1 (en) * 1993-02-25 1994-08-26 Akinori Sumi Human serum albumin and process for producing the same
SE9301583D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Yeast strain and methods for expressing heterologous proteins in yeast
JP3702474B2 (ja) 1994-06-01 2005-10-05 三菱ウェルファーマ株式会社 血清アルブミン製剤の製造方法
DK0699687T3 (da) * 1994-08-31 2004-04-26 Mitsubishi Pharma Corp Fremgangsmåde til oprensning af rekombinant humant serumalbumin
JPH09209303A (ja) 1996-02-05 1997-08-12 Hokkaido Supuritsuton Kogyo Kk 舗装ブロック
AU4837996A (en) 1996-02-29 1997-09-16 Delta Biotechnology Limited High purity albumin production process

Also Published As

Publication number Publication date
DE69611445D1 (de) 2001-02-08
DE69632353D1 (de) 2004-06-03
US5728553A (en) 1998-03-17
JP2006342169A (ja) 2006-12-21
ATE265469T1 (de) 2004-05-15
AU4838096A (en) 1996-12-11
KR100566606B1 (ko) 2006-12-01
JP4372813B2 (ja) 2009-11-25
CN100443499C (zh) 2008-12-17
CN1198844C (zh) 2005-04-27
CN1550504A (zh) 2004-12-01
MX9709108A (es) 1998-06-30
EP1031578B1 (en) 2004-04-28
AU698409B2 (en) 1998-10-29
US20080009042A1 (en) 2008-01-10
ES2219257T3 (es) 2004-12-01
EP1031578A3 (en) 2001-01-17
KR20040077917A (ko) 2004-09-07
JP4040088B2 (ja) 2008-01-30
KR19990021994A (ko) 1999-03-25
US7601515B2 (en) 2009-10-13
WO1996037515A1 (en) 1996-11-28
EP0828759B1 (en) 2001-01-03
DE69632353T2 (de) 2005-05-04
JP4372772B2 (ja) 2009-11-25
CN100455597C (zh) 2009-01-28
PT828759E (pt) 2001-05-31
CN1880334A (zh) 2006-12-20
HK1072436A1 (zh) 2005-08-26
EP0828759A1 (en) 1998-03-18
JP2008037867A (ja) 2008-02-21
PT1031578E (pt) 2004-08-31
US20050142636A1 (en) 2005-06-30
US7223561B2 (en) 2007-05-29
US6034221A (en) 2000-03-07
CN100584857C (zh) 2010-01-27
CA2220923C (en) 2003-01-07
JP4037174B2 (ja) 2008-01-23
DK0828759T3 (da) 2001-02-26
KR100543612B1 (ko) 2006-01-20
DK1031578T3 (da) 2004-06-01
US20030187226A1 (en) 2003-10-02
CA2220923A1 (en) 1996-11-28
ATE198482T1 (de) 2001-01-15
CN1611513A (zh) 2005-05-04
GR3035651T3 (en) 2001-06-29
EP1031578A2 (en) 2000-08-30
HK1009456A1 (en) 1999-06-04
DE69611445T2 (de) 2001-07-19
US6638740B1 (en) 2003-10-28
JP2003048900A (ja) 2003-02-21
CN1191545A (zh) 1998-08-26

Similar Documents

Publication Publication Date Title
ES2156991T3 (es) Procedimiento de produccion de albumina de elevada pureza.
CA2183888A1 (en) Antibody purification
CA2265935A1 (en) Heat shock protein complexes
CA2099138A1 (en) Chondroitinase, Process for Preparing the Same, and Pharmaceutical Composition Comprising the Same
CA2388716C (en) Process for the purification of pharmacologically active proteins through cationic exchange chromatography
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
KR900701823A (ko) 혈장단백질의 크로마토그래피 분리법
AU2572688A (en) Process for the purification of serum albumin
DE69521752D1 (de) Verfahren für die Herstellung von Proteinen
WO2003030821A3 (en) Albumin fusion proteins
CA2350327A1 (en) Methods of purifying recombinant human erythropoietin from cell culture supernatants
AU3075995A (en) Process for modifying the stability of antibodies
EP0239565A3 (en) Method of and apparatus for separating proteins
ES8504837A1 (es) Procedimiento de separacion de las principales proteinas de la sangre hemolizada
AU4764385A (en) Method for silver staining proteins and nucleic acids
ATE131490T1 (de) Verfahren zur herstellung von gereinigten albuminlösungen
Fridriksson et al. Electrospray mass spectra from protein electroeluted from sodium dodecylsulfate polyacrylamide gel electrophoresis gels
CA2223702A1 (en) Therapeutic fragments of von willebrand factor
AU6092498A (en) Recombinant fusion proteins based on ribosome-inactivating proteins of european mistletoe (viscum album)
ATE272072T1 (de) Verfahren zur reinigung von menschlichem interleukin-1 rezeptor antagonist aus rekombinanten e.coli
CA2274241A1 (en) A process for purifying apolipoprotein a or apolipoprotein e from human plasma
EP0892045A3 (de) Verfahren zur Herstellung eines eine Hyaluronidase enthaltenden Präparats
NZ326494A (en) Production of an immunoglobulin enriched fraction from whey protein solutions using a cation exchanger
JPS57147056A (en) Method for analysis of amino acid

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 828759

Country of ref document: ES